Neumora clears toxicology repeat in 162-animal rat study, targets NMRA-215 IND filing for Q4 2026
Zero unexpected in-life adverse findings across 162 rats in a repeat 13-week study removes the primary obstacle for NMRA-215, Neumora Therapeutics' (Nasdaq: NMRA) oral NLRP3 inhibitor targeting obesity and cardiometabolic disease. The…
By Warren Ashby·Jul 27, 2026·2 min read·regulatory·NMRA
Source: sec.gov
© 2026 NewsMeter
Regulatory · NIKISep 6, 2026
Niki BioSolutions installs post-merger C-suite with $320,000 COO base and 800,000-share option grant
2 min
Regulatory · NVDASep 6, 2026
Nvidia in talks to acquire Hugging Face for $12.9 billion
1 min
Regulatory · METASep 5, 2026
Meta agrees to proposed $17 billion settlement over children's harm as documentary mocks Hasidic smartphone restrictions
2 min